Myopax receives special FDA status for potential treatment of rare congenital disease
Myopax has received the FDA’s rare pediatric disease designation for a potential treatment associated with the rare exstrophy-epispadias complex.
German stem cell company Myopax, which last year was granted a convertible loan of EUR 1.3m from Danish life science incubator BioInnovation Institute (BII), has this week received a special status from the US Food and Drug Administration (FDA), according to a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
